Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

2.13
+0.15007.58%
Pre-market: 2.130.00000.00%08:28 EDT
Volume:9.18M
Turnover:19.63M
Market Cap:79.71M
PE:-1.45
High:2.22
Open:2.06
Low:2.04
Close:1.98
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:1.33
T/O Rate:52.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.70
PE(LYR):-1.59

Loading ...

Tenax Therapeutics Amends Executive Employment Agreements to Expand Severance, Change-in-control Benefits

Reuters
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Biohaven Ltd. (BHVN) and BioLife Solutions (BLFS)

TIPRANKS
·
Jun 25

Tenax Therapeutics Price Target Maintained with a $35.00/share by Cantor Fitzgerald

Dow Jones
·
Jun 24

Tenax Therapeutics Initiated at Buy by Chardan Capital

Dow Jones
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Abbott Laboratories (ABT) and AbbVie (ABBV)

TIPRANKS
·
Jun 22

Tenax Therapeutics price target raised to $40 from $34 at Guggenheim

TIPRANKS
·
Jun 22

Chardan Initiates Tenax Therapeutics at Buy

MT Newswires Live
·
Jun 22

Tenax Therapeutics initiated with a Buy at Chardan

TIPRANKS
·
Jun 22

Tenax Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jun 13

Tenax Therapeutics price target raised to $50 from $20 at Piper Sandler

TIPRANKS
·
Jun 12

Tenax Therapeutics Announces Results of 2026 Annual Meeting

TIPRANKS
·
Jun 05

Tenax Therapeutics shareholders ratified Cherry Bekaert as independent auditor for 2026

Reuters
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)

TIPRANKS
·
Jun 01

LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)

TIPRANKS
·
May 16

Tenax Therapeutics CFO Thomas R. Staab II files initial beneficial ownership statement

Reuters
·
May 14

Tenax Therapeutics: Buy Rating Reiterated with $27 Price Target Unchanged on Compelling Phase 3 Opportunity

TIPRANKS
·
May 13

Tenax Therapeutics reports Q1 EPS (35c), consensus (40c)

TIPRANKS
·
May 12

Tenax Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Tenax Therapeutics Q1 Net Income USD -15.716 Million

Reuters
·
May 12

Tenax Therapeutics Q1 net loss widens on higher R&D costs

Reuters
·
May 12